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Abstract 
Background: 20% of sentinel lymph node (SLN) positive melanoma patients 
have positive non-SLN lymph nodes in completion lymph node dissection 
(CLND). We investigated SLN tumor load, non-Sentinel-positivity and disease-
free survival (DFS), to assess whether certain patients could be spared CLND. 
Patients and Methods: SLN-biopsy was performed on 392 patients between 
1999 and 2005. Median observation period was 38.8 months. 
Results: SLN tumor load did not predict non-SLN-positivity: 30.8% of patients 
with SLN macro metastases (mets) (≥2mm) and 16.4% with micro mets (≤2mm) 
had non-SLN-positivity (p=0.09). Tumor recurrences after positive SLNs were 
more than twice as frequent for SLN macrometastases (51.3%) than for 
micrometastases (24.6%) (p=0.005). For patients with SLN micrometastases the 
DFS-analysis was worse (p=0.003) when comparing those with positive non-
SLNs (60% recurrences) to those without (17.6% recurrences). This difference 
did not translate into significant differences in DFS: Patients with SLN 
micrometastasis either with (p=0.022) or without additional positive non-SLNs 
(P<0.0001,) fared worse than patients with tumor-free SLNs. 
Conclusions: The 2mm-cut-off for SLN tumor load accurately predicts 
differences in DFS in contrast to non-SLN-positivity in CLND. Therefore, no 
recommendations concerning discontinuation of CLND based on SLN tumor 
load can be deduced. 
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Introduction 
In the past decades, the incidence of cutaneous malignant melanoma has risen 
steadily accompanied by an increase in mortality in male patients {MacKie et al., 
2007, Br J Cancer, 96, 1772-7}. Due to major prevention efforts, the numbers 
seem to stabilize in younger age groups {MacKie et al., 2007, Br J Cancer, 96, 
1772-7}. Early diagnosis has increased the proportion of thin melanomas with a 
greater likelihood for cure {McMasters and Swetter, 2003, J Surg Oncol, 82, 209-16}. 
However, the overall melanoma-specific survival remains unaffected despite all 
endeavors towards improving medical care. Much attention has been focused 
on the management of the regional lymph nodes (RLN) in melanoma patients. 
In this context, the surgical management strategies of the RLN have undergone 
considerable change in the past; with lymphatic mapping and sentinel lymph 
node (SLN) identification being the most relevant contribution {Cabanas, 1977, 
Cancer, 39, 456-66}{Morton et al., 1992, Arch Surg, 127, 392-9; Wong et al., 1991, 
Ann Surg, 214, 637-41}. Based on the concept that the regional lymphatics serve 
as a barrier, temporarily trapping the orderly tumor spread from the primary site 
to more distant locations, it was proposed that the histopathological status of 
the SLN would accurately predict melanoma metastases {Reintgen et al., 1994, 
Ann Surg, 220, 759-67; Thompson et al., 1995, Melanoma Res, 5, 255-60}. Today, 
SNB is the most important staging tool, because the status of the SLN presents 
the most important prognostic factor for recurrence and survival for melanoma 
patients and identifies patients, who might benefit from further therapy, such as 
complete lymph node dissection (CLND) and adjuvant interferon therapy {Balch 
et al., 2001, J Clin Oncol, 19, 3622-34; Hafner et al., 2004, Br J Dermatol, 150, 677-86; 
Morton et al., 1999, Ann Surg, 230, 453-63 discussion 463-5}. {Eggermont AM, 2007, 
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I, 25, No. 
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18S , 8504}.  
Nevertheless, the impact of SLNB on survival remains unclear. Recently, 
Morton et al. reported an increased disease free survival with no significant 
impact on over-all survival {Morton et al., 2006, N Engl J Med, 355, 1307-17}, 
raising the question whether lymph node dissection is necessary in case of a 
positive SLN. The identification of predictive factors for non-SLN positivity is a 
challenge in order to spare SLN-positive patients the morbidity of CLND. Unlike 
the situation for cutaneous melanoma, widely accepted guidelines exist for 
breast cancer, which no longer recommend CLND in patients with an SLN-sub-
micrometastasis (<0.2mm), since these they are highly unlikely to recur 
regionally {Fournier et al., 2004, Ann Surg, 239, 859-63 discussion 863-5; Rutgers, 
2004, Br J Surg, 91, 1241-2}. We communicate our SLNB experience during a 7-
year period, particularly focusing on SLN tumor load, non-SLN-positivity and 
patterns of tumor recurrence.  
 
Patients and Methods 
Patients 
392 patients with cutaneous malignant melanoma underwent SLNB, from the 
introduction of the method in our institution in October 1999, to December 2005, 
and were followed up until September 31st, 2006. The median period of 
observation was 38.8 months.  
 
Technique of SLN Identification, Wide Excision and Sentinel Lymph Node 
Biopsy 
Most patients had already undergone diagnostic excision of the tumor. All 
patients underwent WE wide excision of the primary tumor with a safety margin 
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of 1 cm for Breslow thickness below 2 mm, and a safety margin of 2 cm for 
Breslow thickness above 2 mm, in accordance with Swiss guidelines {Dummer 
et al., 2005, Dermatology, 210, 39-44}. Neither the triple technique used to identify 
and remove the SLNs nor the methodology employed for pathological analysis 
of the removed lymph nodes differs from that previously described in the 
literature {Hafner et al., 2004, Br J Dermatol, 150, 677-86; Morton et al., 2005, Ann 
Surg, 242, 302-11 discussion 311-3}. Consistent with published guidelines 
{Cochran et al., 2000, Cancer, 89, 236-41}, SLNB was recommended for 
pathological staging of the RLN in patients with a minimal Breslow of 1.00 mm 
and no clinical or radiological evidence of melanoma metastasis at the time of 
diagnosis. SLNB was equally performed in 15 Patients with a smaller tumor 
thickness, for whom the referring dermatologist urged staging, either because 
the Breslow value was only slightly below 1.00 mm, or histological review 
revealed aggravating factors. CLND was recommended for positive SLNs, 
according to the Augsburg Consensus guidelines {Cochran et al., 2000, Cancer, 
89, 236-41}. Clinicopathologic characteristics were analyzed, including sex, age, 
location of the primary tumor, Breslow value and size of metastatic depots. 
Disease-free survival (DFS) and primary recurrences were determined 
separately for SLN positive and SLN negative patients according to the 
anatomic location of the first recurrence. Local recurrences were defined as 
satellite recurrence within or up to 3 cm around the wide excision scar; in-transit 
recurrence was defined as recurrence in the dermal lymphatics between the site 
of the excised primary tumor and the RNB. Recurrences within the staged 
regional nodal basin were considered RNB recurrences and distant recurrences 
as distant skin, nodal or systemic recurrences beyond the staged RNB. 7 
patients with positive SLNB refused to undergo CLND.  
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Follow-up 
Patients were all followed-up in our outpatient clinic, until aftercare for all 
surgical procedures, including the complications thereof, could safely be 
terminated. Oncological follow-up was performed in the Department of 
Dermatology according to Swiss national guidelines using a standardized 
sequence of imaging techniques {Dummer et al., 2005, Dermatology, 210, 39-44}. 
Recurrences were registered and patients treated according to the site of 
recurrence, surgically, systemically or by radiotherapy.  
 
Technique of histopathological SLN work-up 
After one day of fixation the SLN was bisected along the long axis of the hilar 
region. If the SLN was thick the two halves were further cut in 2mm thick 
sections. Depending on its size the bisected node was embedded in one or 
more paraffin blocks. Paraplast sections at 5 intervals of 50 m were prepared 
from each paraffin block. From each paraplast section four slides were made 
and stained with Haematoxylin-Eosin and immune stained with antibodies to S-
100, HMB-45 and Pan Melanoma Plus acoording the EORTC recommendations 
for working-up melanoma SLNs. {Cook et al., 2003, J Pathol, 200, 314-9}. 
Haematoxylin – Eosin and immune stained sections of all samples were 
reviewed by one experienced pathologist (DM). There were four different 
diagnoses based on the recommendations of the International Union against 
Cancer: (i) no tumour, (ii) isolated tumour cells, (iii) micrometastasis (< 2 mm), 
and (iv) macrometastasis (> 2 mm) {Hermanek et al., 1999, Cancer, 86, 2668-73}. 
Since no significant differences between patients with isolated tumor cells and 
patients with micrometastsis were found, we have summarized both groups 
under the heading of micrometastasis for this analysis, as described in previous 
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studies {Carlson et al., 2003, Ann Surg Oncol, 10, 575-81; Pearlman et al., 2006, Am J 
Surg, 192, 878-81; Roka et al., 2007, Eur J Surg Oncol}.  
 
Statistical Analysis 
Statistical analysis was performed using SPSS 13. Statistical comparison  
between two groups of patients was done using a t-test for continuous  
variables and a chi-square test for categorical variables. Breslow  
thickness was log-transformed to reach an approximate normal distribution.  
Comparison of groups with respect to the endpoint "time to recurrence" has  
been done using Kaplan-Meier curves and a logrank test. For the  
relationship between a continuous variable (like log Breslow thickness)  
and time to recurrence, a Cox regression has been calculated. P-values  
below 0.05 were considered as significant.  
 
Results 
Patient characteristics and regional lymph node basin status 
Baseline patient characteristics are summarized in table 1. Male patients were 
significantly older at the time of diagnosis (p<0.0001, t-test). Breslow values for 
both sexes do not differ significantly (p=0.60, t-test). Analysis of the location of 
the primary tumor correlated well with gender-specific differences previously 
described2, with the lower extremity as the most common melanoma site in 
females, and the trunk in males (p<0.0001, chi-square test). A total of 470 hot 
nodes were identified, on average 1.2 SLN (range 1 – 3) were removed per 
patient. A total of 427 RNB were staged in our 392 patients, as in 31 patients, 
lymphocintigraphy identified SLNs in two RNBs, and 2 patients had hot nodes in 
3 RNBs simultaneously. We staged 221 axillary RNBs, 146 in the groin and 52 
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in the head and neck area. Intercalated nodes (popliteal fossa, cubital fossa, 
medial bicipital sulcus, lateral chest wall) were identified in 8 patients (2%), in 6 
(1.5%) of them in conjunction with either additional inguinal or axillary SLNs. All 
of these intercalated nodes were tumor-free. The rate of major complications 
mandating either additional surgery or stationary hospital care was 2.3%. A total 
of 114 positive SLN (24.5%) in 107 Patients (27.3%) were found. 
Micrometastatic tumour deposits were found in 66 of 107 (61.7%) patients with 
positive SLNs, while macrometastases were found in 41 (38.3%) patients. Out 
of 66 patients with micrometastases 11 presented isolated tumor cells (10.3%). 
Table 2 displays a comparison, stratified by age, sex and Breslow thickness, of 
SLN positive and SLN negative patients. Neither gender was significantly 
associated with a higher rate of positive SLNs nor, consequently, with a gender-
dependant significantly worse prognosis (p=0.84, chisquare test). No statistically 
significant differences were evident for median and mean age in SLN positive 
and SLN negative groups (p=0.23, t-test). Both mean and median Breslow 
thickness were significantly greater in the SLN positive group (p<0.0001, t-test). 
Stratification of the SLN positive patients according to Breslow values (Table 3) 
revealed increasing rates of SLN positivity proportional to greater thickness of 
the primary tumor. Influence of the Location of the primary tumor on SLN 
positivity was statistically insignificant (Table 4) (p=0.38, chisquare test). CLND 
was recommended to all 107 patients with positive SLNs. 100 (93.5%) 
underwent the procedure, 7 (6.5%) refused and their data was not included for 
the outcome analysis of the SLN-positive group. 
 
SLN-Positive Patients - CLND results 
We performed a total of 102 CLNDs on 100 patients, as 1 patient had bilateral 
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axillary CLNDs, and 1 patient had bilateral groin CLNDs simultaneously. In all, 
46.1% of all CLNDs were axillary (47/102), 42.2% were in the groin (43/102) and 
11.8% were neck dissections (12/102). No additional positive non-SLN was 
found in 78% (78/100) of the CLNDs, whereas 22% (22/100) had additional 
positive nodes. SLN tumor load did not effectively predict non-SLN-positivity in 
CLND: 30.8% (12/39) of the CLND patients with a macrometastasis in their 
sentinel had further non-SLN-positivity. In comparison, 16.4% (10/61) of those 
patients with a SLN micrometastasis, had a positive CLND (p=0.09, chisquare 
test). 
 
SLN-positive Patients – Melanoma recurrence 
65% (65/100) of patients, who underwent CLND, remained disease-free, 35% 
(35/100) presented a tumor relapse: Median time to recurrence was 12.5 
months (range 3 – 43 months). Primary sites of recurrence were local or in-
transit (9/35, 25.7%), nodal (11/35, 31.4%), and distant (15/35, 42.9%).  Patients 
without further positive non-SLNs had significantly less recurrent disease 
(26.9%, 21/78), compared to those with additional positive non-SLNs in CLND 
(14/22, 63.3%) (p=0.001, logrank test) (cf. Table 5 and Fig. 1a). The effect of 
tumor load on recurrence was pronounced: In general, recurrence rates in the 
SLN positive group were 35.0%, and 10.9% in the SLN negative group, the 
difference being highly significant (p<0.0001, logrank test) (cf. Fig. 1d). Among 
the SLN positive patients, tumor recurrences after a positive SLNB were more 
than twice as frequent for SLN macrometastases (51.3%, 20/39) than for 
micrometastases (24.6%, 15/61), the difference being significant in a DFS 
analysis (p=0.005, logrank test) (cf. Fig. 1b). Stratified by size of SLN metastasis 
and number of additional positive non-SLNs in the CLND, the impact of SLN 
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tumor load becomes even more evident: 51 of the 78 patients with no further 
positive lymph node in the CLND had micrometastatic tumor depots in their 
SLNs; 9 of them (17.6%) suffered a relapse. This rate was significantly higher 
and more than doubled for the 27 patients in whom the SLN, although remaining 
the only positive lymph node even after CLND, harbored a macrometastasis: 12 
patients (44.4%) exhibited tumor recurrences (p=0.009, logrank test). Even 
more impressive was the correlation between additional positive non-SLNs in 
CLND and tumor recurrence: 66.7% (8/12) of all patients with SLN-
macrometastases and 60% (6/10) of patients with SLN-micrometastases who 
had positive non-SLNs in CLND relapsed during the mean follow-up period of 
38.8 months. The influence of additional positive non-SLNs aggravated tumor 
recurrence only by increasing total tumor burden and did not exert more 
prognostic influence than SLN tumor burden alone: Patients with SLN-
macrometastases and positive non-SLNs did not have significantly more tumor 
recurrences compared to those with SLN-micrometastases and positive non-
SLNs (p=0.60). SLN tumor burden did, however, influence recurrence 
significantly when analyzing micro- and macrometastases separately: Whereas 
for patients with SLN macrometastases, the difference in the development of 
tumor recurrences did not differ significantly (p=0.17) between patients with 
(recurrence 66.7%, 8/12) or without (recurrence 44.4%, 12/27) additional non-
SLNs in CLND, for patients with SLN micrometastes the DFS-analysis was 
significantly worse when comparing those with additional non-SLNs (60% 
recurrences, 6/10) to those without (17.6% recurrences, 9/51)  (p=0.003, log-
rank test). This difference did not, however, correspond to significant differences 
in DFS: Both patients with SLN micrometastasis either with (p=0.022, log-rank 
test) or without additional positive non-SLNs (P<0.0001, log-rank test) fared 
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significantly worse than patients with tumor-free SLNs (cf. Fig. 1c). 
For Breslow thickness, another indicator for tumor load, there was also 
correlation with tumor recurrence: For intermediate thickness melanomas 
(Breslow 1-4 mm), the rate of recurrence after positive SLNB remained within 
similar margins. (Table 3). In 27.5% (11/40) of the patients with a primary tumor 
thickness of 1-2 mm, the tumor relapsed, as well as in 33.3% (11/33) of the 
patients with a primary Breslow of 2-4mm. The rate of recurrence, however, 
increased sharply for positive SLNs associated with a primary melanoma thicker 
than 4 mm: Every second (50%, 12/24) recurred after CLND. The percentage of 
micro- and macrometastases, however, remained fairly constant and did not 
increase proportionally with Breslow thickness (Table 3) (p=0.23, t-test). 
 
Negative Patients 
During the median period of observation of 38.8 months, 89.1% (254) of the 285 
negative patients showed DFS. 10.9% (31), however, exhibited recurrences and 
the SLNB was therefore considered false-negative (FN). Identical false-negative 
rates were noted for distant (4.2%, 12/31) and nodal primary recurrence. Local 
or in-transit relapse was seen in 2.5% (7/31). All of the RNBs, in which SLNB 
was performed, yielded similar rates of false-negative results. 7.7% (17/221) of 
all staged axillary RNBs produced false-negative results, 6.2% (9/146) were 
from SLNBs in the groin and 9.6% (5/52) came from Head and Neck RNBs. 
Median time to recurrence for false-negative SLNB patients was 23 months: 24 
month for primary distant relapse, 19 for primary nodal failure and 16 for local 
and in-transit recurrence.  
 
Discussion 
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In this single centre retrospective analysis, we reviewed our experience with 
SLNB in cutaneous melanoma. Our well-characterized patient population was 
treated and followed using a structured algorithm, and compares well with other 
series published. Our main objective was to study the correlation between SLN 
tumor load and further non-SLN-positivity as well as DFS.  
Consistent with our own data (78%) 67-90% of SLN-positive patients do not 
have further non-SLNs that contain tumor deposits in the CLND specimens 
{Carlson et al., 2003, Ann Surg Oncol, 10, 575-81; Reintgen et al., 1994, Ann Surg, 
220, 759-67; van Akkooi et al., 2006, Ann Oncol, 17, 1578-85}. As a consequence, 
the majority of SLN-positive patients undergoes unnecessary surgery 
associated with considerable morbidity {Guggenheim et al., 2008, Ann Surg, 247, 
687-693}. Therefore, several authors have tried to identify patient, tumor and 
SLN characteristics predicting further non-SLN positivity in order to spare CLND 
{Carlson et al., 2003, Ann Surg Oncol, 10, 575-81; Scolyer et al., 2007, Ann Oncol, 18, 
806-8; van Akkooi et al., 2006, Ann Oncol, 17, 1578-85}. Although CLND has not 
yet been proven to positively influence overall melanoma-specific survival, 
Cascinelli et all have recently shown that CLND is necessary to achieve the 
best assessment of prognosis of stage IB and II melanoma and to identify those 
patients who, having only positive sentinel nodes and negative nonsentinel 
nodes, have a good prognosis {Cascinelli et al., 2006, J Clin Oncol, 24, 4464-
71}. Whereas previous studies have failed to consistently identify the same 
clinicopathological features as indicators for additional non-SLN positivity upon 
CLND or for DFS {Scolyer et al., 2007, Ann Oncol, 18, 806-8}, SLN tumor load, 
nevertheless, was uniformly confirmed by all of these studies as prognosticator 
for non-SLN positivity and recurrence. Thus, we focus our analysis on this 
characteristic.  
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There is considerable debate as to how to stratify SLN tumor burden. Several 
authors have reported that submicroscopic SLN tumor burden may be without 
prognostic significance or even judged as SLN-negative: Satzger et al. {Satzger 
et al., 2007, Am J Surg Pathol, 31, 1175-80} found that isolated 
immunohistochemically positive tumor cells are without prognostic significance 
and DFS of these patients did not differ from that of SLN-negative patients, an 
observation which is supported in a broader sense by Van Akkooi et al. {van 
Akkooi et al., 2006, Ann Oncol, 17, 1578-85} In their study, no patient with an SLN 
tumor load of <0.1mm had additional non-SLN-positivity upon CLND, and 5-
year overall survival was 100%. On the basis of these data, they suggested that 
such patients may be considered SLN-negative and should be spared CLND. A 
similar observation, albeit with a cut-off <0.2mm, was made by Govindarajan et 
al. {Govindarajan et al., 2007, Ann Surg Oncol, 14, 906-12} Both studies did, 
however, either not reach statistical significance (Van Akkooi) or the study 
population was relatively small (Govindarajan). Yet another cut-off based on a 
novel micromorphometric classification, albeit this time at 1mm above sub-
microscopic levels, was proposed by Starz et al {Starz et al., 2004, Ann Surg 
Oncol, 11, 162S-8S}. In his studies, patients with deposits <1mm had survival 
rates not significantly different from those of patients with tumor-free SLNs. As 
these results proved to be difficult to reproduce, however, all these observations 
are contested by other authors {Scheri et al., 2007, Ann Surg Oncol, 14, 2861-6; 
Scolyer et al., 2007, Ann Oncol, 18, 806-8}. Scheri {Scheri et al., 2007, Ann Surg 
Oncol, 14, 2861-6} found that 12% of their patients with isolated tumor cells had 
further positive non-SLNs in their CLND-specimens and that their melanoma-
specific survival was significantly worse than in those patients with negative 
SLNs.  
Formatiert: Englisch
(Großbritannien)
Formatiert: Englisch
(Großbritannien)
Formatiert: Englisch
(Großbritannien)
Kommentar [D4]: Diesen 
Abschnitt ev ganz weglassen. Wir 
habenunsere Bedingunegn ja 
definitiert.. 
Gelöscht: ,
Gelöscht: however, 
 14 
The failure to predict the necessicity of CLND based on sub-microscopic SLN 
tumor load is demonstrated by several studies: Carlson et al. {Carlson et al., 
2003, Ann Surg Oncol, 10, 575-81}, reported that 22.6% of patients with isolated 
tumor cells had further positive non-SLNs upon CLND. Although the numbers 
are too small to reach significance, our own data from patients with isolated 
tumor cells indicate that indeed submicroscopic cut-offs and micromorphometric 
classifications may not contribute much towards clarifiying behavioural and 
prognostic differences according to SLN tumor burden. Of the 11 patients with 
isolated tumor cells in our series, only 1 (9.1%) had additional positive non-
SLNs, but 3 (27.3%) had tumor recurrence during follow-up. The cut-off 
separating micrometastases from macrometastases at 2mm, as put forth by 
Hermanek et al {Hermanek et al., 1999, Cancer, 86, 2668-73}, however, may allow 
more promising conclusions. Several authors have used this cut-off in analysing 
their study populations. Despite the fact that 6% of the patients with 
micrometastases (isolated tumor cells not differentiated) in their SLNs had a 
positive CLND, Pearlman et al. {Pearlman et al., 2006, Am J Surg, 192, 878-81} 
found that their 5-year survival was at 85% essentially the same as that of 
patients with a negative SLNB. Carlson et al. {Carlson et al., 2003, Ann Surg 
Oncol, 10, 575-81} have made a similar observation: Even though SLN tumor 
burden was not predictive of non-SLN-positivity, the 3-year overall survival for 
patients with SLN tumor burden ≤2mm (including isolated tumor cells) was 
significantly higher than for those with SLN tumor deposits of >2mm (90% vs. 
57%), irrespective of whether patients had positive CLNDs or not. Roka et al. 
{Roka et al., 2007, Eur J Surg Oncol} were able to partly confirm this: even though 
no significant association between SLN tumor load and non-SLN-positivity was 
found, the rate of DFS for patients with a SLN tumor burden of >2mm was 
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significantly worse. Similar observations come from a study by Ranieri et al. 
{Ranieri et al., 2002, Ann Surg Oncol, 9, 975-81}, albeit with a cut-off at 3mm. Our 
own data confirms these results in part: SLN tumor burden with a cut-off at 2mm 
was indeed a significant prognosticator for tumor recurrence (p=0.005, logrank 
test), with the rates of relapse during the median observation period more than 
twice as frequent for SLN macrometastases (51.3%) as for micrometastases 
(24.6%). Moreover, even though there was no association between SLN tumor 
burden and additional non-SLN-positivity, there was a clear statistical trend 
(p=0.09) in our study indicating that patients with higher SLN tumor burden 
might be associated twice as likely with non-SLN-positivity. This finding confirms 
a similar trend demonstrated by Roka et al. that may reach statistical 
significance once analyzed in larger study populations {Roka et al., 2008, Eur J 
Surg Oncol, 34, 82-8}. The rates for positive CLNDs were not significantly 
different for SLN macrometastases and micrometastases. This is in accordance 
with other studies in which reproducible prediction of non-SLN positivity on the 
basis of SLN tumor burden remained elusive {Carlson et al., 2003, Ann Surg Oncol, 
10, 575-81; Pearlman et al., 2006, Am J Surg, 192, 878-81; Ranieri et al., 2002, Ann 
Surg Oncol, 9, 975-81; Roka et al., 2007, Eur J Surg Oncol}. Additional positive non-
SLNs upon CLND are widely recognized to adversely influence prognosis 
{Carlson et al., 2003, Ann Surg Oncol, 10, 575-81}. In our study, tumor recurrences 
were significantly more frequent in patients with additional positive non-SLNs in 
CLND than in those who did not have a positive CLND. Although our study 
confirms that predicting non-SLN-positivity on the basis of SLN tumor load is 
unreliable, it demonstrates that SLN tumor burden has an impact on DFS. 
Recent experimental studies using melanoma cell lines in mice, have 
impressively shown that melanoma cells can switch their transcriptional profile 
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from an invasive migrating one to a proliferative profile associated with 
melanocytic differentiation ( Hoek et al. Cancer Res. 2008). We hypothesize that 
the evaluation of the invasive markers in melanoma mets might improve the 
predictive accuracy of the SN status. 
 
Today, neither clinicopathological nor histomorphometrical characteristics 
reliably and reproducibly predict non-SLN-positivity in CLND. However, in 
accordance with several other authors, our study supports the observation that 
the cut-off at 2mm for SLN tumor load serves to accurately predict differences in 
DFS. In contrast to other studies, however, patients with SLN tumor burden 
≤2mm did have DFS significantly worse than those with tumor-free SLNs. 
Although far from allowing conclusions, our study illustrates that we do not as of 
yet sufficiently understand what constitutes relevant nodal disease. Even 
though CLND has not been proven to improve survival, pending the results of 
MSLT-II, no clinical recommendations concerning the discontinuation of CLND 
based on SLN tumor load can be deduced. 
 
 
 
 
Gelöscht: Although there is 
some discrepancy over the exact 
cut-off point, there is consensus 
regarding the behavioural and 
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to SLN metastasis size and 
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Gelöscht: SLN-tumor load 
stratified along a cut-off at 2mm 
was reported to correlate with 
DFS irrespective of positive non-
SLNs. Although such a 
correlation was evident for SLN 
micrometastases in our series, 
which were associated with a 
significantly increased DFS 
when compared to SLN 
macrometastases, every single 
stratification according to SLN 
tumor burden (with and without 
additional positive non-SLNs), 
showed worse rates of DFS for 
any group of patients with 
positive SLNs when compared to 
SLN-negative patients. ¶
Gelöscht: Conclusion:¶
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